A new study in the peer-reviewed Journal of Child and Adolescent Psychopharmacology estimated the incidence of neuroleptic malignant syndrome (NMS), a potentially fatal adverse effect of antipsychotic treatment, among individuals ages 5-24 years.
Eye Drops for Presbyopia Win FDA Approval
The FDA approved pilocarpine hydrochloride ophthalmic solution (Qlosi) for adults with presbyopia, according to a statement from Orasis Pharmaceuticals. The approval allows for daily or
October 19, 2023